8-K
filed June 10, 2026, 4:02 PM ET
ticker AQST
CIK 0001398733
other material
confidence high
sentiment neutral
materiality 0.15
Aquestive Therapeutics shareholders elect three Class II directors at 2026 annual meeting
Aquestive Therapeutics, Inc.
- Gregory B. Brown, M.D. elected with 41,373,033 votes for; 1,222,711 against.
- John S. Cochran elected with 36,914,899 votes for; 5,680,845 against.
- Abigail L. Jenkins elected with 39,094,166 votes for; 3,501,578 against.
- Advisory say-on-pay proposal passed: 37,798,609 for, 3,192,381 against.
- KPMG LLP ratified as independent auditor for FY 2026 with 78,804,323 votes for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Aquestive Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2026-06-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified. Votes For Votes Against Votes Abstaining 78,804,323 910,690 346,313
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Aquestive Therapeutics, Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-10 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year. Votes For Votes Against Votes Abstaining Broker Non-Votes 37,798,609 3,192,381 1,604,754 37,465,582
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Aquestive Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The following director nominees were elected to serve as Class II members of the Board of Directors, to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes Gregory B. Brown, M.D. 41,373,033 — 1,222,711 37,465,582 John S. Cochran 36,914,899 — 5,680,845 Abigail L. Jenkins 39,094,166 — 3,501,578
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.